Growing knowledge of Alzheimer’s-linked proteins

Amyloid imaging has held center stage in research into the process of Alzheimer’s disease (AD), but studies presented at last month’s Alzheimer's Association International Conference revealed how far tau imaging has come as well as new insights into yet another protein implicated in AD.

At the conference, Keith Johnson, MD, from Massachusetts General Hospital in Boston, and colleagues presented results of one of the largest tau PET studies of its kind to assess the effect tau deposits in the brain had on declining memory in subjects with normal cognitive function. A total of 56 adults were included in the study.

Results showed that higher levels of tau were associated with declining memory function, suggesting that tau deposition could help identify AD before the onset of symptoms.

Another study presented at the conference focused not on tau or amyloid, but on a protein newly suspected of impacting neurodegenerative disease. This protein, called TAR DNA binding protein of 43kDa (TDP-43), was studied by Keith Josephs, MD, from the Mayo Clinic in Rochester, Minn., and colleagues.

Josephs and colleagues looked at autopsy data from 342 subjects who had been diagnosed with AD. Of these patients, nearly 200 had TDP-43 deposition, and those who did were up to 10 times more likely to suffer cognitive decline by the time of their death compared with those who did not have such deposits.

The researchers said the findings suggested that TDP-43 amplifies memory loss and hippocampal atrophy in AD and is a key player in the neurodegenerative process.

We’ll continue to watch as more research is conducted on the impact of TDP-43 and tau in the years ahead.

-Evan Godt
Editor – Health Imaging

Evan Godt
Evan Godt, Writer

Evan joined TriMed in 2011, writing primarily for Health Imaging. Prior to diving into medical journalism, Evan worked for the Nine Network of Public Media in St. Louis. He also has worked in public relations and education. Evan studied journalism at the University of Missouri, with an emphasis on broadcast media.

Around the web

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.